Flucytosine Capsules, USP are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine.
From the U.S. FDA-approved label for Flucytosine. Full label: DailyMed.
Flucytosine Capsules, USP are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules, USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules, USP (see MICROBIOLOGY ).
From the U.S. FDA-approved label for Flucytosine. Full label: DailyMed.
The usual dosage of Flucytosine Capsules, USP is 50 to 150 mg/kg/day administered in divided doses at 6-hour intervals. Nausea or vomiting may be reduced or avoided if the capsules are given a few at a time over a 15-minute period. If the BUN or the serum creatinine is elevated, or if there are other signs of renal impairment, the initial dose should be at the lower level (see WARNINGS ).
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Flucytosine Capsules, USP should not be used in patients with a known hypersensitivity to the drug.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Flucytosine Capsules, USP must be given with extreme caution to patients with impaired renal function. Since flucytosine is excreted primarily by the kidneys, renal impairment may lead to accumulation of the drug. Flucytosine serum concentrations should be monitored to determine the adequacy of renal excretion in such patients. Dosage adjustments should be made in patients with renal insufficiency to prevent progressive accumulation of active drug. Flucytosine Capsules, USP must be given with extreme caution to patients with bone marrow depression.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The adverse reactions which have occurred during treatment with Flucytosine Capsules, USP are grouped according to organ system affected. Cardiovascular: Cardiac arrest, myocardial toxicity, ventricular dysfunction. Respiratory: Respiratory arrest, chest pain, dyspnea. Dermatologic: Rash, pruritus, urticaria, photosensitivity.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
2 products from 2 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Cytoflu 500mg Tablet | Flucytosine (500mg) | Jolly Healthcare | bottle of 100 tablets |
| Cytorx 500mg Tablet | Flucytosine (500mg) | Cipla Ltd | strip of 10 tablets |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store at 25°C (77°F); KEEP OUT OF REACH OF CHILDREN Sigmapharm Laboratories, LLC Bensalem, PA 19020 OS010A-03 REV.0219
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
